Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Trillium Therapeutics Inc. (TRIL)

0.29   0.028 (10.69%) 11-19 13:00
Open: 0.3 Pre. Close: 0.262
High: 0.3 Low: 0.2665
Volume: 390,729 Market Cap: 8M
Trillium Therapeutics Inc is an immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc and CD200 monoclonal antibody targets immuno regulatory pathways that tumor cells exploit to evade the host immune system.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.28 - 0.282 0.282 - 0.283
Low: 0.247 - 0.248 0.248 - 0.249
Close: 0.258 - 0.26 0.26 - 0.262

Technical analysis

as of: 2019-11-19 1:01:48 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0.36     One year: 0.42
Support: Support1: 0.27    Support2: 0.24
Resistance: Resistance1: 0.31    Resistance2: 0.36
Pivot: 0.27
Moving Average: MA(5): 0.28     MA(20): 0.27
MA(100): 0.32     MA(250): 0.78
MACD: MACD(12,26): -0.01     Signal(9): -0.01
Stochastic oscillator: %K(14,3): 61.90     %D(3): 61.72
RSI: RSI(14): 52.60
52-week: High: 3.20  Low: 0.24  Change(%): -89.5
Average Vol(K): 3-Month: 20598  10-Days: 21373

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
TRIL has closed below upper band by 3.3%. Bollinger Bands are 60.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to TRIL's normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2019-10-22
Trillium Therapeutics Announces Corporate Restructuring and Provides CD47 Program Update
Trillium Therapeutics Inc. (Trillium, "the company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced corporate restructuring to extend the company’s cash runway and to focus on critical value-creating

2019-05-22
The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive late-stage results for its colorectal cancer combo drug) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 21) Adamis Pharmaceuticals Corp (NASDAQ: ADMP )(announced a patent litigation against it for its naloxone injection product candidate that is currently under regulatory review) BioCryst Pharmaceuticals, Inc (NASDAQ: BCRX )( reacted to late-stage study data for its hereditary angioedema prevention candidate) Cancer Genetics Inc (NASDAQ: CGI ) (reacted to its first-quarter results) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Hookipa Pharma Inc (NASDAQ: HOOK ) (reacted to its first-quarter results) Ocular Therapeutix Inc (NASDAQ: OCUL ) ( reported negative Phase 3 readout for glaucoma treatment candidate) Theravance Biopharma Inc (NASDAQ: TBPH ) (reported Phase 1b data of its gut-selective pan-Janus kinase inhibitor TD-1473 at the Digestive Disease Week 2019) Trillium Therapeutics Inc (NASDAQ: TRIL ) Stock In Focus Tocagen's Brian Cancer Gene Therapy Trials Continue With Modification Tocagen Inc (NASDAQ: TOCA ) announced the Phase 3 trial evaluating its Toca 511 and Toca FC gene therapies in patients with recurrent high grade glioma continues without modification.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 28.04
Shares Float (M) 21.61
% Held by Insiders 0.26
% Held by Institutions 40.67
Shares Short (K) 37
Shares Short P. Month (K)

Stock Financials

EPS -2.548
Book Value (p.s.) 0.090
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm) -44.6
Return on Equity (ttm) -78.8
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E -0.11
P/E Growth Ratio 0.09
P/BV 3.18
P/S
P/CF

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2014-11-20
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.